Arrowhead Pharmaceuticals, Inc. $ARWR Position Increased by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 90.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 775,717 shares of the biotechnology company’s stock after purchasing an additional 368,073 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.56% of Arrowhead Pharmaceuticals worth $26,754,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. PNC Financial Services Group Inc. grew its stake in shares of Arrowhead Pharmaceuticals by 3.1% in the 3rd quarter. PNC Financial Services Group Inc. now owns 10,924 shares of the biotechnology company’s stock valued at $377,000 after buying an additional 326 shares in the last quarter. State of Wyoming raised its position in Arrowhead Pharmaceuticals by 5.6% during the third quarter. State of Wyoming now owns 9,519 shares of the biotechnology company’s stock valued at $328,000 after acquiring an additional 504 shares in the last quarter. Arizona State Retirement System lifted its stake in Arrowhead Pharmaceuticals by 1.9% in the third quarter. Arizona State Retirement System now owns 32,661 shares of the biotechnology company’s stock valued at $1,126,000 after acquiring an additional 620 shares during the last quarter. CWM LLC grew its position in Arrowhead Pharmaceuticals by 6.7% in the third quarter. CWM LLC now owns 12,179 shares of the biotechnology company’s stock worth $420,000 after acquiring an additional 764 shares in the last quarter. Finally, Resona Asset Management Co. Ltd. increased its stake in shares of Arrowhead Pharmaceuticals by 8.7% during the 2nd quarter. Resona Asset Management Co. Ltd. now owns 11,218 shares of the biotechnology company’s stock worth $180,000 after purchasing an additional 900 shares during the last quarter. 62.61% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Arrowhead Pharmaceuticals

In related news, Director Mauro Ferrari sold 7,530 shares of the stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $70.00, for a total value of $527,100.00. Following the completion of the transaction, the director owned 69,053 shares of the company’s stock, valued at $4,833,710. This represents a 9.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider James C. Hamilton sold 40,164 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $63.11, for a total value of $2,534,750.04. Following the completion of the sale, the insider directly owned 171,958 shares in the company, valued at approximately $10,852,269.38. This represents a 18.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 502,086 shares of company stock worth $33,109,648 in the last three months. Company insiders own 3.60% of the company’s stock.

Arrowhead Pharmaceuticals Stock Down 0.2%

ARWR opened at $63.27 on Friday. The business has a 50 day moving average of $66.12 and a 200-day moving average of $48.55. The stock has a market capitalization of $8.86 billion, a price-to-earnings ratio of 41.35 and a beta of 1.21. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.29. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $9.57 and a 1-year high of $76.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The company had revenue of $264.03 million during the quarter, compared to the consensus estimate of $225.66 million. During the same period last year, the company earned ($1.39) earnings per share. Arrowhead Pharmaceuticals’s revenue for the quarter was up 10461.3% on a year-over-year basis. As a group, sell-side analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ARWR shares. Weiss Ratings raised shares of Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday, February 6th. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 10th. Chardan Capital increased their price objective on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Piper Sandler reissued an “overweight” rating and issued a $110.00 price objective (up from $100.00) on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, January 13th. Finally, Morgan Stanley boosted their target price on Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 7th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $81.67.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.